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Abstract
Small molecule inhibitors of signaling pathways have
proven to be extremely useful for the development of
therapeutic strategies for human cancers. Blocking
the tumor-promoting effects of transforming growth
factor-B (TGF-B) in advanced stage carcinogenesis pro-
vides a potentially interesting drug target for thera-
peutic intervention. Although very few TGF-B receptor
kinase inhibitors (TRKI) are now emerging in preclinical
studies, nothing is known about how these inhibitors
might regulate the tumor-suppressive or tumor-
promoting effects of TGF-B, or when these inhibitors
might be useful for treatment during cancer progres-
sion. We have investigated the potential of TRKI in new
therapeutic approaches in preclinical models. Here, we
demonstrate that the TRKI, SB-431542, inhibits TGF-B–
induced transcription, gene expression, apoptosis, and
growth suppression. We have observed that SB-431542
attenuates the tumor-promoting effects of TGF-B,
including TGF-B–induced EMT, cell motility, migration
and invasion, and vascular endothelial growth factor
secretion in human cancer cell lines. Interestingly,
SB-431542 induces anchorage independent growth of
cells that are growth-inhibited by TGF-B, whereas it
reduces colony formation by cells that are growth-
promoted by TGF-B. However, SB-431542 has no effect
on a cell line that failed to respond to TGF-B. This
represents a novel potential application of these inhi-
bitors as therapeutic agents for human cancers with
the goal of blocking tumor invasion, angiogenesis, and
metastasis, when tumors are refractory to TGF-B–
induced tumor-suppressor functions but responsive
to tumor-promoting effects of TGF-B.
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Introduction
Small molecule inhibitors are very useful in understanding
the role of individual signaling pathways involved in differ-
ent biologic processes. These molecules have the potential
to be useful for therapeutic applications [1]. There is com-
pelling evidence indicating that TGF-b has complex roles
in tumor suppression and progression that are context-
dependent and stage-dependent. TGF-b plays a tumor-
suppressive role by its ability to maintain tissue architecture,
inhibit growth, induce apoptosis, and inhibit genomic instability
in nontransformed cells or tissues. Several lines of evidence
suggest that carcinoma cells frequently lose antiproliferative
response to TGF-b and increase the production of one or more
of the TGF-b isoforms. High levels of TGF-b can promote tumor
growth in an autocrine and/or paracrine manner through the
suppression of immunosurveillance, stimulation of connective
tissue formation and angiogenesis, and changes that favor
invasion and metastasis. Blocking the tumor-promoting effects
of TGF-b by small molecule inhibitors provides an excellent
therapeutic opportunity to improve the treatment of cancer.
The most desirable approach for developing new therapeutic
strategy by targeting TGF-b signaling would be to retain
TGF-b–induced tumor suppression function, but to block
TGF-b signaling in advanced invasive and metastatic cancers.
The transforming growth factor-b (TGF-b) family of poly-
peptides regulates a wide variety of biologic functions including
cell proliferation, differentiation, matrix formation, and apop-
tosis [2,3]. The multifunctional effects of TGF-b are elicited
through oligomeric complex formation between the type I and
type II serine– threonine kinase receptors. TGF-b initiates
signals by binding to the type II receptor (TbRII) and stabilizes
the heteromeric complex with the type I receptor (TbRI) and, as
a result, TbRI is transphosphorylated and activated by TbRII.
The activated TbRI then propagates the signals through inter-
action with, and phosphorylation of, receptor-associated
Smads [4]. The Smad proteins are divided into three distinct
classes based on their structure and function in signaling by
TGF-b family members. Receptor-regulated Smads (R-Smad)
are phosphorylated on two serine residues at the C-terminus
and thus activated in a ligand-specific manner. Smad2 and
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Smad3 mediate signaling by TGF-b and activin, whereas
Smad1, Smad5, and presumably Smad8 are known to be
involved in BMP signaling. Smad4 functions as a common
mediator of TGF-b, activin, and BMP signaling pathways
[2,3]. On phosphorylation by type I receptors, R-Smads form
heteromeric complexes with Smad4 and translocate to the
nucleus where they modulate the transcription of TGF-b
target genes [4–7]. A distinct class of distantly related
Smads, including Smad6 and Smad7, has been identified
as consisting of inhibitors of these signaling pathways, and
these inhibitors function by interfering with the activation of
R-Smads. TGF-b–mediated Smad signaling has been
shown to be required for the antiproliferative activity of
TGF-b, and components in this signaling pathway are fre-
quently inactivated by mutation or silenced in several human
cancers [8]. In addition to activating the Smad pathway,
TGF-b can also induce other signaling pathways like
p38MAPK, ERK, PI3K, JNK, or Rho, which may be important
for pro-oncogenic activities with low levels of input signal.
Many TGF-b–inducible pro-oncogenic pathways are either
independent of Smads, or require cooperation between the
Smad and alternative pathways under transforming condi-
tions [9,10]. The possibility of blocking tumor-permissive
effects of TGF-b signaling, which involves multiple autocrine
and paracrine mechanisms, provides an attractive target for
therapeutic intervention. Although pan-TGF-b neutralizing
antibodies and TbRII-Fc fusion protein have been used in
preclinical studies, they did not show much promise as
anticancer drugs due to complex roles of TGF-b signaling
[11]. Interestingly, studies with soluble TbRII-Fc did not
report any tumor-promoting actions or inflammatory re-
sponses in vivo, whereas inhibition of TGF-b signaling by
this soluble antagonist decreased invasion, migration, and
cell survival [12,13]. Small molecule inhibitors of TGF-b
function could have potential regarding drug specificity and
efficacy in therapeutic interventions. In this regard, a potent
inhibitor of TbRI kinase activity (SB-431542) [14], which has
no direct effect on the components of the ERK, JNK, or p38
MAP kinase pathways or components of the signaling path-
ways activated by serum, has recently been developed. SB-
431542 is a specific inhibitor of TGF-b superfamily type I
receptors ALK4 (activin receptor– like kinase 4), ALK5,
and ALK7 [15,16]. However, it is not yet known how these
inhibitors might regulate the tumor-suppressive or tumor-
promoting effects of TGF-b, or under what circumstances
these inhibitors might be useful for treatment during cancer
progression. In the present study, we demonstrate that SB-
431542 inhibits TGF-b–induced apoptosis and growth sup-
pression in several cell types. SB-431542 efficiently blocks
the tumor-promoting effects of TGF-b including cell motility,
migration, invasion, and vascular endothelial growth factor
(VEGF) secretion in human cancer cell lines. SB-431542
increases the anchorage-independent growth of lung adeno-
carcinoma cells (A549) that are responsive to TGF-b–
induced growth inhibition. Interestingly, this inhibitor reduces
colony formation by late-stage colon cancer cells (HT29),
whose growth is otherwise promoted by TGF-b. SB-431542
has no effect on colony formation by VMRC-LCD cells that
are unresponsive to TGF-b. Hence, inhibition of TGF-b
receptor kinase activity may be a new avenue for potential
therapy in human cancers that are resistant to TGF-b tumor-
suppressor function.
Materials and Methods
Cell Lines and Cultures
Human colon cancer–derived nontumorigenic FET cells
(a kind gift from Dr. Brattain), mink lung epithelial cells
(Mv1Lu), human kidney cells (293T), human hepatoma
cells (HepG2), mouse mammary epithelial cells (NMuMG),
human breast cancer cells (MDA-MB 231), pancreatic
adenocarcinoma cells (PANC-1), human keratinocyte cells
(HaCaT), and rat intestinal epithelial cells (RIE) were main-
tained in DMEM containing 10% fetal bovine serum (FBS)
supplemented with 50 U/ml penicillin and 50 mg/ml strep-
tomycin solution. Stable RIE-iRas cells were cultured and
maintained as before [17]. Human lung adenocarcinoma
cells (A549), TbRII null human lung cancer cells (VMRC-
LCD), and human colon adenocarcinoma cells (HT29)
were maintained in RPMI with 10% FBS supplemented with
penicillin/streptomycin and L-glutamate. All cell lines were
cultured and maintained at 37jC in a humidified incubator in
the presence of 5% CO2.
Reagent
The TGF-b receptor kinase inhibitor, SB-431542, was
kindly provided by Dr. Nicholas J. Laping from GlaxoSmith-
Kline (King of Prussia, PA). SB-431542 was also purchased
from Tocris Cookson, Inc. (Ellisville, MO).
Transcriptional Response Assay
FET cells were transiently transfected with CMV-bgal, and
p3TP-Lux or (CAGA)9MLP-Luc reporter plasmids. HepG2
cells were transiently transfected with CMV-bgal, and p21-
Luc or PAI-1-Luc plasmids. Transfected cells were incubated
in 0.2% FBS with 5 ng/ml TGF-b1 in the presence of SB-
431542 for 22 hours. Cell lysates were used to measure both
luciferase and b-gal activities, and the normalized luciferase
activity was presented.
Immunoprecipitation and Western Blot Analyses
293T, FET, and A549 cells were serum-starved for
2 hours and treated with 12.5 ng/ml TGF-b1 in the pres-
ence of SB-431542 for 1 hour. Cells were solubilized in
lysis buffer. An equal amount of each protein lysate was
incubated with both anti-Smad2 and anti-Smad3 poly-
clonal antibodies for 2 hours at 4jC, followed by incuba-
tion with 20 ml of protein G-Sepharose beads (Sigma
Biochemicals, St. Louis, MO) for 1 hour. The immune com-
plexes were analyzed by Western blot analysis with mouse
anti-Smad4 antibody. Protein lysates were also analyzed
by Western blot analysis with anti–phospho-Smad2 (Up-
state, Inc., Lake Placid, NY), anti-Smad2 (Zymed Labo-
ratories, Inc., San Francisco, CA), anti-Smad3 (Zymed
Laboratories, Inc.), anti-Smad4 (Santa Cruz Biotechnology,
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Inc.), and mouse anti–b-actin (Sigma Biochemicals, St.
Louis, MO) antibodies. For other Western blots, extracts
were prepared from RIE, RIE-iRas, Mv1Lu, and NMuMG
cells treated with TGF-b1 in the presence of SB-431542 as
indicated in figure legends.
Nuclear and Cytoplasmic Extracts
Subcellular localizations of endogenous Smad proteins
were analyzed by subcellular fractionation. A549 cells
were treated with TGF-b in the presence of SB-431542 for
either 30 or 90 minutes, and nuclear and cytoplasmic frac-
tions were made according to the manufacturer’s protocol
(Pierce, Rockford, IL). An equal amount of cytosolic or
nuclear extracts (20 mg/lane) was separated in SDS-PAGE
and analyzed by Western blot analysis using antibodies
against Smad2, Smad3, and Smad4. Complete fractiona-
tions of cytoplasmic and nuclear proteins were verified by
Western blot analysis with antibodies against Rho-GDI and
PARP (Santa Cruz Biotechnology, Inc.).
[3H]Thymidine Incorporation Assay
FETandMDA-MB-231 cellswere treatedwithTGF-b in the
presence of SB-431542 for 26 hours in 10% FBS containing
DMEMmedium. An amount of 4 mCi/well [3H]thymidine (NEN,
Boston, MA) was added in each well for an additional 2 hours.
Cells were then fixed in 10% cold trichloroacetic acid (TCA),
washed, and lysed in 0.2 NNaOH. Radioactivity incorporated
into TCA-insoluble [3H]thymidine was measured by scintilla-
tion counting and then presented.
Cell Counting Assay
Mv1Lu, MDA-MB-231, A549, VMRC-LCD, and HT29
cells were seeded into 12-well plates. Cells were then treated
with TGF-b in the presence of SB-431542 (10 mM) for a
total of 6 days. TGF-b and/or SB-431542 containing media
was replaced every other day. Cells were counted each day
and the average cell numbers from triplicate measurements
were plotted.
Flow Cytometric Analysis
Cells from each pool of FET, RIE, and Mv1Lu were
seeded into 60-mm plates and allowed to attach for 24 hours.
Cells were then treated with 5 ng/ml TGF-b1 in the presence
of SB-431542 in 10% FBS-containing medium for 35 hours.
Cells were harvested, washed, and suspended in 200 ml of
cold phosphate-buffered saline (PBS). One milliliter of pro-
pidium iodide cocktail [containing 50 mg/ml propidium iodide
(Sigma Biochemicals), 1 mg/ml sodium citrate, 5 ml/ml Triton
X-100, and 5 mg/ml RNase A in PBS] was added to each cell
suspension and incubated on ice for 30 minutes. Cells were
analyzed for red fluorescence through a 620-nm LP filter.
Red fluorescence was used as a marker of DNA content and
cell cycle status. The percentage of cells present in different
phases of the cell cycle was measured and analyzed.
DNA Laddering
HepG2 cells were serum-starved for 24 hours and treated
with 5 ng/ml TGF-b1 in the presence of SB-431542 (2 mM) for
46 hours. Cells (floating and adherent) were collected and
lysed. RNase A (5 mg/ml) was added to the clear lysate and
incubated at 56jC for 2 hours. Proteinase K (200 mg/ml) was
then added and incubated at 50jC for an additional 2 hours.
Treated samples were extracted twice with TE-saturated
phenol/chloroform. DNA was precipitated with cold ethanol,
washed, suspended in 20 ml of TE buffer, and analyzed by
agarose gel electrophoresis.
Cell Death ELISA
HepG2 cells (20,000 per well) were seeded into 12-well
plates and allowed to attach for 20 hours. Cells were serum-
starved for 20 hours and then treated with 5 ng/ml TGF-b1
in the presence of SB-431542 for 24 hours. Cells (floating
and adherent) were lysed in 200 ml of lysis buffer. Each lysate
(10 ml) was used for ELISA (Roche Molecular Biochemicals,
Indianapolis, IN).
Immunofluorescent Detection
Immunofluorescent staining was performed according to
published method [18]. Briefly, NMuMG and PANC-1 cells
were grown into chamber slides, and treated with 5 ng/ml
TGF-b1 in the presence of SB-431542 (10 mM) for 24 hours
for NMuMG and 60 hours for PANC-1 cells. Cells were fixed
in ice-cold 100% methanol and then permeabilized in PBS
containing 0.2% Triton X-100 for 10 minutes. Nonspecific
sites were blocked with 3% BSA for 1 hour at room tempera-
ture. Cells were incubated with E-cadherin (1:1000) and ZO1
(1:300) primary antibodies for 2 hours at room temperature.
After washing, cells were incubated for 1 hour with second-
ary antibody conjugated with Cy3 (Sigma Biochemicals) at
room temperature. Cells were washed with PBS and visual-
ized by fluorescence microscope. The intracellular localiza-
tion of endogenous Smad proteins was studied using HaCaT
cells as described above. Nuclei were stained with DAPI
(Vector Laboratories, Burlingame, CA).
Cell Migration Assay
A549 cells were seeded in the upper chamber of 8-mM
pore transwells coated with collagen and conditioned me-
dium was added as a chemoattractant in the lower chamber.
Cells were incubated with 5 ng/ml TGF-b1 in the presence of
SB-431542 in 4% FBS media for 5 hours. Cells that migrated
through the pores of the filter were stained and counted from
six random fields of view at 400magnification, and the data
were expressed as the average number of cells per field
of view.
Cell Invasion Assay
For invasion through collagen layer, the upper surface of
8-mM pore transwell chamber was overlaid with 100 mg of
collagen dissolved in 100 ml of PBS, and dried overnight. For
invasion through Matrigel (BD Biosciences, San Diego, CA)
layer, 40 ml (f100 mg) of diluted Matrigel solution was
overlaid on the upper surface of the abovementioned trans-
well chambers. TheMatrigel was allowed to gel by incubating
the plates for at least 2 hours at 37jC. Thereafter, A549
(30,000) cells in a volume of 100 ml of RPMI media containing
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0.2% BSA were added to the upper chamber of each well.
Four percent FBS containing RPMI media with 5 ng/ml
TGF-b1 in the presence of SB-431542 was used as a chemo-
attractant in the lower chamber as mentioned above, and
then incubated at 37jC for 21 hours. Cells that invaded
through the filter were stained and counted from six random
fields of view at 200 magnification and the data were
expressed as the average number of cells per field of view.
Wound Healing Assay
MDA-MB-231 cells (2  105) were seeded into 12-well
plates and allowed to attach for 20 hours. Cells were then
serum-starved for 32 hours prior to wounding. Plastic tips
were used to make wounding across the cell monolayer.
Wounded cells were treated with 3 ng/ml TGF-b1 in the
presence of SB-431542 for 30 hours. Phase contrast pic-
tures were taken by an inverted microscope using a magni-
fication of 200.
ELISA for VEGF and TGF-1
A total of 100,000 cells from each pool of A549 and HT29
were seeded into each well of 12-well plate. Cells were
cultured in media containing 0.2% FBS for 18 hours, and
then treated with 5 ng/ml TGF-b1 in the presence of SB-
431542 (10 mM) in 0.5 ml of media for 24 hours. One hundred
microliters of each supernatant media was used for VEGF
assay according to the manufacturer’s instruction (R&D Sys-
tems, Minneapolis, MN). For TGF-b1 ELISA, 100,000 cells
from each pool of A549, VMRC-LCD, and HT29 were seeded
into each well of 12-well plates and serum-starved for
20 hours. Cells were then treated with SB-431542 in 0.5 ml
of serum-free RPMI media for 24 hours. One hundred micro-
liters of each supernatant media was activated and used for
TGF-b1 assay according to the manufacturer’s instruction
(R&D Systems).
Soft Agarose Assay
A total of 5 103 cells from each pool of A549 and VMRC-
LCD, and 10  103 cells from HT29 were suspended in 1 ml
of 0.4% sea plaque agarose containing 10% FBS medium
and then plated on the top of 1 ml of semisolidified 0.8%
agarose in the same medium in 35-mm plates. Plates were
incubated for 2 weeks at 37jC in the presence of 5% CO2 in
a humidified incubator. SB-431542 (10 mM) was added on
the top agar layer every fourth day. Colonies grown on soft
agarose were counted by automated colony counter, and the
pictures of colonies on soft agarose were taken.
Results
SB-431542 Prevents TGF-–Induced Complex Formation
between Smad2/3 and Smad4, and Blocks Nuclear
Translocation of Smad2 and Smad3
To determine the potential role of SB-431542 on down-
stream TGF-b signaling, we tested its ability in blocking
functional complex formation between Smad2/3 and Smad4
in vivo. Lysates from 293T, FET, and A549 cells were sub-
jected to anti-Smad2/3 immunoprecipitation followed by
immunoblotting with anti-Smad4 antibodies. TGF-b1 induced
the complex formation between Smad2/3 and Smad4 in
all cell types. Treatment of cells with SB-431542 blocked
TGF-b– induced complex formation in a dose-dependent
manner (Figure 1A, top panel). The reduced Smad complex
formation by the inhibitor was due to blockade of TGF-b–
induced phosphorylation and activation of Smad2/3, as
shown in Figure 1A, second panel. To determine the effect
of the inhibitor on TGF-b–mediated nuclear translocation
of Smad proteins, we analyzed the cytoplasmic (C) and
nuclear (N) fractions after treating A549 cells with TGF-b
and/or SB-431542. TGF-b induced nuclear translocation of
Smad2, Smad3, and Smad4 within 30 minutes, and this
was blocked by SB-431542. SB-431542 alone did not show
any effect on the localization of Smad proteins (Figure 1B).
Complete separation of cytoplasmic and nuclear proteins
was tested by Western blot analysis for RhoGDI and PARP,
respectively. We also found similar results in Mv1Lu, RIE,
and NIH-3T3 cell lines (data not shown). To further deter-
mine the subcellular localization of endogenous Smad2 and
Smad3, HaCaT cells were treated with TGF-b in the pres-
ence of SB-431542 for 1 hour and analyzed by immuno-
fluorescence using anti-Smad2 and anti-Smad3 antibodies.
It is clear that, after TGF-b stimulation, Smad2 and Smad3
translocate to the nucleus, as shown in Figure 1C. SB-
431542 blocked TGF-b–mediated nuclear transport of
Smad2 and Smad3 and, as a result, Smad2 and Smad3 re-
mained predominantly in the cytoplasm (Figure 1C). These
results demonstrate that SB-431542 blocks TGF-b–induced
complex formation between Smad2/3 and Smad4, and the
nuclear translocation of Smad2 and Smad3.
SB-431542 Blocks TGF-–Induced
Transcriptional Responses
To test whether the inhibition of Smad complex forma-
tion affects downstream transcriptional responses mediated
by TGF-b, we performed transient transfection assays
using TGF-b–responsive reporters p3TP-Lux and (CAGA)9-
MLP-Luc. TGF-b strongly induced reporter activities in both
FET (Figure 2A) and Mv1Lu cells (data not shown).
SB-431542 blocked these TGF-b1–mediated transcrip-
tional responses in a dose-dependent manner. To examine
whether SB-431542 has a similar effect on natural pro-
moters, we performed transient transfection assays with
two TGF-b–sensitive gene promoter reporters, p21 Cip1
and PAI-1. SB-431542 blocked TGF-b–induced p21 Cip1
and PAI-1 promoter activation (Figure 2, B and C). These
results suggest that SB-431542 inhibits the activation
of Smad pathway and blocks TGF-b–induced transcrip-
tional responses.
SB-431542 is a Potent Inhibitor of TGF-–Regulated
Protein Expression
To investigate the effect of SB-431542 on endogenous
protein expression induced by TGF-b, we treated Mv1Lu
and RIE cells with TGF-b and/or SB-431542 and tested
the expressions of p21 Cip1, PAI-1, and fibronectin using
512 SB-431542 in Tumor Suppression Halder et al.
Neoplasia . Vol. 7, No. 5, 2005
Western blot analyses, as shown in Figure 3, A and B. TGF-b
induced the expression of PAI-1 protein in both cell types,
and SB-431542 inhibited the induction of PAI-1 by TGF-b in a
dose-dependent manner (Figure 3, A and B). SB-431542
also inhibited TGF-b–mediated upregulation of fibronectin
and p21 Cip1 (Figure 3, A and B) and decreased down to
basal level. These data, in combination with the results
discussed above, indicate that SB-431542 is a potent inhibi-
tor of TGF-b–induced transcription and gene regulation.
Effect of SB-431542 on Tumor-Suppressor
Functions of TGF-
One of the most important biologic effects of TGF-b is its
ability to inhibit proliferation of many cell types, including
most epithelial cells [19]. However, under transforming con-
ditions, the growth of tumor cells is occasionally stimulated
by TGF-b. We examined whether SB-431542 inhibits TGF-b–
induced growth arrest by [3H]thymidine incorporation assay
(Figure 4A). TGF-b alone shows a strong inhibition of
[3H]thymidine incorporation in FET cells by 91% at a con-
centration of 1.0 ng/ml. SB-431542 inhibited this TGF-b–
induced inhibition of [3H]thymidine incorporation from 91%
to 40% at 2 mM concentration (Figure 4A). We then examined
the ability of SB-431542 to block the TGF-b–mediated inhi-
bition of cell proliferation by cell counting over the duration of
culture for 6 days (Figure 4B). TGF-b efficiently suppressed
the growth of Mv1Lu cells, whereas SB-431542 significantly
blocked TGF-b–induced growth inhibition (Figure 4B). To
examine whether SB-431542 promotes cells from G0–G1
phase to S phase by blocking TGF-b–induced G1 arrest, we
performed flow cytometric analyses by propidium iodide
staining of FET, RIE, and Mv1Lu cells. TGF-b1 strongly
arrested cells in the G0–G1 phase of the cell cycle with
corresponding decrease of cells in the S phase. SB-431542
significantly suppressed TGF-b–induced G1 arrest and in-
duced the accumulation of more cells in the S phase of the
cell cycle (Figure 4C).
Cell proliferation and programmed cell death are tightly
regulated in normal cells, and disruption of this balance may
eventually lead to the development of tumors. TGF-b acts
as a potent inducer of apoptosis, and this TGF-b–induced
apoptosis is cell type–specific. To further characterize
whether SB-431542 is able to inhibit TGF-b–induced apo-
ptosis, we performed a quantitative cell death ELISA assay
Figure 1. Effect of SB-431542 in blocking TGF- signaling. (A) Immunoprecipitation. 293T, FET, and A549 cells were treated with 12.5 ng/ml TGF-1 in the presence
of SB-431542 (SB) for 1 hour. Cell lysates were subjected to immunoprecipitation with anti-Smad2 and anti-Smad3 polyclonal antibodies, and the immunoprecipitates
were analyzed byWestern blot analysis with anti-Smad4 antibody (top). Cell lysates were subjected toWestern blot analysis with anti –phospho Smad2, anti-Smad2,
anti-Smad3, and anti-Smad4 antibodies (bottom section). An equal amount of protein loading was verified by Western blot analysis with anti –-actin monoclonal
antibody. Each experiment was repeated four times. (B) Nuclear translocation of Smad proteins was analyzed by separating cytoplasmic (C) and nuclear (N) fractions
after treating A549 cells with TGF- and/or SB-431542 for either 30 or 90 minutes. Smad proteins were detected by Western blot analysis using antibodies against
Smad2, Smad3, and Smad4. Complete fractionations of cytoplasmic and nuclear proteins were verified byWestern blot analysis with antibodies against Rho-GDI and
PARP. (C) Blockade of TGF- – induced nuclear import of Smad2 and Smad3 by SB-431542 in HaCaT cells as detected by immunofluorescence. Cells were serum-
starved and treated with TGF- in the presence of SB-431542 for 1 hour and processed for immunofluorescence using either anti-Smad2 or anti-Smad3 polyclonal
antibodies. Fluorescence was visualized by antirabbit antibody conjugated to Cy3 using a Zeiss Axioplan fluorescence microscope. Nuclei of the same cells were
stained with DAPI. Each experiment was repeated four times.
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as well as qualitative DNA laddering with HepG2 cells.
This cell line is known to be responsive to TGF-b–induced
apoptosis [20]. TGF-b induced apoptosis in these cells by
four-fold (Figure 4D). At 2 mM concentration, SB-431542
completely blocked TGF-b1– induced apoptosis. We also
found that TGF-b induced a significant amount of DNA frag-
mentation in HepG2 cells, which was efficiently abrogated
by SB-431542 (Figure 4E ). Taken together, these data sug-
gest that treatment with SB-431542 inhibits TGF-b–induced
tumor-suppressor functions including regulation of growth
and apoptosis.
SB-431542 Inhibits TGF-–Induced EMT in NMuMG and
PANC-1 Cells
The increased expression and activation of TGF-b by
tumor cells profoundly induce the progression of epithelial
tumors to the metastatic stage by altered cellular plasticity,
loss of cell –cell contacts, increased cell migration and
invasion, and degradation of the extracellular matrix. Epi-
thelial to mesenchymal transition (EMT) in epithelial cells
is characterized by the acquisition of spindle morphology
and increased motility with the loss of tight and adherens
junctions. To examine the effect of SB-431542 on TGF-b–
induced EMT, we used mouse mammary epithelial cells
(NMuMG). TGF-b treatment changes the cell morphology
from cuboidal to an elongated spindle-like shape within
24 hours (Figure 5A, top panel), consistent with previous
studies [18]. SB-431542 inhibited TGF-b–induced EMT and
delocalization of E-cadherin and ZO1 proteins from cellular
junctions (Figure 5A). We then verified whether disruption of
cell–cell adhesions was due to the altered expression of
junctional proteins. No detectable changes in the expression
of E-cadherin and b-catenin were observed by either TGF-b
or the inhibitor (Figure 5B). Interestingly, the expression of
ZO1 was downregulated by TGF-b, which was restored
by SB-431542 in a dose-dependent manner (Figure 5B).
We observed a similar SB-431542–mediated blockade of
EMT and delocalization of E-cadherin in pancreatic adeno-
carcinoma cells (PANC-1) induced by TGF-b (Figure 5C).
TGF-b induced EMT in PANC-1 cells as described previously
[21]. We further determined the expression of junctional
E-cadherin protein, and we found that E-cadherin is down-
regulated by TGF-b in PANC-1 cells. Under similar conditions,
we did not observe any change in the level of ZO1 (data not
shown). Interestingly, SB-431542 treatment completely re-
stored TGF-b– induced downregulation of E-cadherin in
PANC-1 cells (Figure 5D). These data suggest that TGF-b–
mediated EMT, together with the delocalization of junctional
molecules, can be blocked by SB-431542.
SB-431542 Blocks TGF-–Induced Tumor Cell Migration
and Invasion
TGF-b is known to stimulate chemotaxis and migration of
tumor cells [22,23], although not all tumor cell lines are
responsive to TGF-b–induced migration and invasion. In an
attempt to study the effect of SB-431542 on TGF-b–mediated
cell migration and invasion, we observed that TGF-b stimulated
the chemotactic migration of lung adenocarcinoma (A549)
cells by three-fold through a polycarbonate membrane
(Figure 6A). SB-431542 completely blocked TGF-b–induced
migration of A549 cells. TGF-b enhanced the invasion of
A549 cells by three-fold through the collagen membrane
(Figure 6B), whereas a six-fold increase in invasion of A549
cells was observed through Matrigel barrier (Figure 6C).
However, SB-431542 strongly attenuated TGF-b–mediated
Figure 2. Effect of SB-431542 in blocking TGF- – induced reporter gene
activation. (A) Reporter assay. FET cells were transiently transfected with
CMV--gal and p3TP-Lux or (CAGA)9MLP-Luc reporter plasmids. Cells
were then treated with 5 ng/ml TGF-1 in the presence of SB-431542 (0.5,
3, and 10 M) for 22 hours. Luciferase activity was normalized to -gal
activity, and the relative luciferase activity was expressed as the mean ± SD
of triplicate measurements. (B and C) Reporter assay. HepG2 cells were
transiently transfected with CMV--gal and p21-Luc (B) or PAI-1-Luc (C)
plasmids. Cells were treated with 5 ng/ml TGF-1 in the presence of SB-
431542 (0.5, 2, and 10 M) for 22 hours. Cell lysates were analyzed for both
luciferase and -gal activities as mentioned above. Each experiment was
repeated four times.
Figure 3. SB-431542 blocks TGF- – induced PAI-1, fibronectin (FN), and
p21 CIP1 expression. (A) Mv1Lu cells were serum-starved for 16 hours and
treated with 5 ng/ml TGF-1 in the presence of SB-431542 for 6 hours. Cell
lysates were analyzed by Western blot analysis with anti –PAI-1 and anti-FN
antibodies. (B) RIE cells were treated as above and cell lysates were
analyzed by Western blot analysis with anti –PAI-1 (Torrey Pines Biolabs,
Inc., Houston, TX) and anti-p21 (Santa Cruz Biotechnology, Inc.) antibodies.
An equal amount of protein loading was verified by Western blot analysis with
anti –-actin antibody. Each experiment was repeated three times.
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invasion in a dose-dependent manner. At 10 mM concen-
tration, it blocked both basal and TGF-b–induced invasion
in these cells. We further examined the role of SB-431542 in
blocking TGF-b–induced cell migration by a wound healing
experiment using the breast carcinoma cell line, MDA-MB-
231. This cell line is responsive to TGF-b in wound healing
experiments as shown before [24]. TGF-b accelerated
wound closure, whereas SB-431542 inhibited TGF-b–
induced cell motility and, as a result, the wound remained
opened (Figure 6D). To verify whether the wound closure in
MDA-MB-231 cells is due to TGF-b–induced proliferation or
TGF-b–induced migration, we performed cell counting and
thymidine incorporation assays, as shown in Figure 6E. Our
results show that MDA-MB-231 cells are growth-inhibited by
about 50% in cell counting experiments (Figure 6E, left) as
reported previously. Thymidine incorporation in these cells
was inhibited by TGF-b (Figure 6E, right). Therefore, prolif-
eration is not involved in the migration of MDA-MB-231 cells
induced by TGF-b.
TGF-b is known to induce tumor-promoting effects under
transforming conditions, sometimes in cooperation with
oncogenic Ras. Numerous studies have suggested that
the induction in COX-2 level in human cancers provides
growth and survival advantage, and increases invasiveness
and angiogenesis. TGF-b synergistically enhances the ex-
pression of COX-2 in conditionally Ha-Ras–transformed
rat intestinal epithelial cells (RIE-iRas) reported previously
[17]. To examine whether SB-431542 can block TGF-b and
Ha-Ras–induced COX-2 expression, we treated RIE-iRas
cells with IPTG and/or TGF-b in the presence or absence
of SB-431542 for 24 hours. IPTG induced activated Ras
expression (Figure 6F, second panel). Activated Ras and
TGF-b either independently or synergistically induced
COX-2 expression in this cells (Figure 6F, top panel).
SB-431542 blocked TGF-b–induced COX-2 expression in
RIE-iRas cells, although IPTG-induced Ha-Ras–mediated
COX-2 expression remained unchanged (Figure 6F), sug-
gesting a role of SB-431542 in an inhibition of TGF-b–
induced COX-2 expression in RIE-iRas cells. Taken together,
these results show that SB-431542 can block the tumor-
promoting effects of TGF-b including cell migration and in-
vasion, and COX-2 expression.
SB-431542 Blocks VEGF Secretion in Human Tumor
Cell Lines
VEGF secretion is upregulated in human tumors and its
secretion is often elevated by TGF-b. We tested whether
SB-431542 has any effect on VEGF production induced by
Figure 4. SB-431542 inhibits TGF- – induced growth suppression and apoptosis. (A) [3H]thymidine incorporation assay. FET cells were treated with TGF-1 in the
presence of SB-431542 for 26 hours and then treated for an additional 2 hours with [3H]thymidine. Cells were fixed in TCA, washed, and lysed in 0.2 N NaOH.
Radioactivity incorporated into TCA-insoluble [3H]thymidine was measured by scintillation counting. Individual data points are the mean ± SD of triplicate
determinations. (B) Cell counting assay. Mv1Lu cells were cultured in DMEM containing 10% FBS and treated with 5 ng/ml TGF-1 in the presence of SB-431542
(10 M) for a total of 6 days. Cells were counted every day and the cell numbers are plotted. Individual data points are the mean ± SD of triplicate determinations.
(C) FACScan analysis. FET, RIE, and Mv1Lu cells were treated with 5 ng/ml TGF-1 in the presence of SB-431542 for 35 hours. Cells were collected and
evaluated for DNA content by flow cytometric analyses. Results are expressed as the mean ± SD of three replicate values of the percentage of cells in different
phases of the cell cycle. (D) Quantitative cell death ELISA. HepG2 cells were treated with 5 ng/ml TGF-1 in the presence of SB-431542 for 24 hours. Cell lysates
were analyzed by cell death ELISA as described in the Materials and Methods section. An individual data point is a representative of the mean ± SD of three
individual measurements. Each experiment is repeated three times. (E) DNA laddering. HepG2 cells were treated with 5 ng/ml TGF-1 in the presence of
SB-431542 (2 M) in serum-free medium for 46 hours. Cells were lysed and fragmented DNA was isolated from the cell lysates. Each DNA was loaded onto
1.6% agarose gel and visualized by staining with ethidium bromide.
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TGF-b in A549 and HT29 cells. These two cell lines produce
good amounts of TGF-b and VEGF. TGF-b induced VEGF
secretion by five-fold in A549 cells within 24 hours, and this
effect was completely blocked by the inhibitor, as determined
by ELISA (Figure 7A). A549 cells produced a significant
amount of TGF-b as shown in Figure 7C. In contrast, in
HT29 cells, exogenous TGF-b induced only 1.7-fold VEGF
secretion. Interestingly, SB-431542 efficiently blocked the
VEGF secretion induced by both exogenous and endoge-
nous TGF-b (Figure 7B). We did not observe any significant
inhibition of basal VEGF secretion in A549 cells (Figure 7A).
We observed that HT29 cells secrete a significant level of
TGF-b (Figure 7C). We further observed that TGF-b secre-
tion in these cells was not significantly blocked by the
inhibitor, suggesting that the blockade of VEGF production
is due to the blockade of signaling from endogenous TGF-b,
and not due to attenuation of the secretion of TGF-b.
Interestingly, we did not observe any alteration in VEGF
secretion in VMRC-LCD cells by either TGF-b or SB-431542
(data not shown), although TGF-b secretion in these cells is
similar to that of A549 and HT29 cells (Figure 7C). These
findings further indicate the therapeutic efficacies of SB-
431542 in blocking the tumor-promoting effects of TGF-b.
Differential Effects of SB-431542 on Anchorage-Independent
Growth of Human Cancer Cell Lines
Anchorage-independent growth in semisolid medium is
considered to be a useful parameter in assessing the malig-
nancy of human cells. To evaluate the effect of blockade of
TGF-b signaling by SB-431542 on anchorage-independent
growth, we performed soft agar assays with three cell lines:
1) A549 cell line that is responsive to the growth-inhibitory
effect of TGF-bl 2) VMRC-LCD cells that lack TbRII and are
not growth-inhibited by TGF-b; and 3) HT29 cells that are
growth-promoted by TGF-b. HT29 and VMRC-LCD cells
produce bigger colonies than that of A549 cells on soft
agarose within 2 weeks (Figure 8, A,C, and E ). Interestingly,
SB-431542 treatment stimulates colony formation in both
number and size by A549 cells, whereas no effect on
colony growth was observed in the case of VMRC-LCD cells
(Figure 8, A, C, and G) when compared with untreated cells.
However, we found that SB-431542 dramatically suppressed
the colony growth of HT29 cells (Figure 8, E and G). In most
human tumors, cells first become resistant to TGF-b–
induced growth inhibition and, later during cancer progres-
sion, high levels of TGF-b can promote tumor growth in an
autocrine and/or paracrine manner. We hypothesized that
blockade of TGF-b–induced autocrine growth-inhibitory ef-
fect in A549 cells might lead to an aggressive tumorigenic
phenotype, whereas abrogation of TGF-b–mediated cell pro-
liferation by SB-431542 in HT29 cells might decrease the
tumorigenic potential. To confirm this, we tested the effects
of TGF-b and the inhibitor on the growth of these three cell
lines. We observed that TGF-b inhibited the growth of A549
cells by 40% and SB-431542 blocked this effect induced
by both exogenous and endogenous TGF-b (Figure 8B).
Figure 5. SB-431542 abrogates TGF- – induced EMT in both NMuMG and PANC-1 cells. (A) NMuMG cells were treated with 5 ng/ml TGF-1 in the presence of
SB-431542 (10 M) for 24 hours. Cells were stained with anti –E-cadherin and anti-ZO1 antibodies, and visualized by antimouse antibody conjugated to Cy3.
Phase contrast images were recorded at 200 magnification. (B) Cell lysates were prepared from NMuMG cells as treated above, and were analyzed by Western
blot analysis with anti –E-cadherin, anti-ZO1, and anti –-catenin antibodies. An equal amount of protein loading was verified by Western blot analysis with anti –
-actin antibody. (C) PANC-1 cells were treated with 5 ng/ml TGF-1 in the presence of SB-431542 (10 M) for 60 hours as described before, fixed, and incubated
with anti –E-cadherin antibody, and visualized by antimouse antibody conjugated to Cy3 as mentioned above. Phase contrast images were recorded at 200
magnification. (D) PANC-1 cells were treated with TGF-1 in the presence of SB-431542 for 24, 48, and 60 hours. Cell lysates were analyzed by Western blot
analysis with anti –E-cadherin antibody. An equal amount of protein loading was verified by Western blot analysis with anti –-actin antibody. Each experiment
was repeated three times with similar results.
516 SB-431542 in Tumor Suppression Halder et al.
Neoplasia . Vol. 7, No. 5, 2005
TGF-b or the inhibitor has no effect on the growth of VMRC-
LCD cell lines (Figure 8D). Interestingly, TGF-b stimulated
the proliferation of HT29 cells. SB-431542 blocked the
growth stimulation mediated by both endogenous and
exogenous TGF-b as evident from [3H]thymidine incorpo-
ration assay (data not shown) and cell counting assay
(Figure 8F ). These data suggest that SB-431542 can en-
hance the tumorigenicity of A549 cells by blocking the
growth-inhibitory effect of TGF-b, whereas it can inhibit the
tumorigenicity of HT29 cells by blocking the tumor-promoting
function of TGF-b. Therefore, SB-431542 may be useful as
a therapeutic agent when tumors lose TGF-b– induced
growth suppression and when tumor-promoting effects of
TGF-b predominate during cancer progression.
Discussion
Increased production of TGF-b in human tumors is corre-
lated with a poor prognosis [25]. Small molecule inhibitors of
TGF-b signaling could be useful for the development of
therapeutic strategies for human cancers. In most human
tumors, cells first become resistant to TGF-b–induced growth
inhibition/apoptosis and, later during cancer progression,
high levels of TGF-b can promote tumor growth in an auto-
crine and/or paracrine manner through the changes that favor
invasion and metastasis. The most desirable approach for de-
veloping a new therapeutic strategy by targeting TGF-b sig-
naling would be to retain TGF-b–induced tumor-suppressor
function, but to block TGF-b signaling in advanced invasive
and metastatic cancers. Previous studies with pan-TGF-b–
neutralizing antibodies and soluble TbRII-Fc fusion protein
suggest that suppression of tumor progression by blocking
TGF-b signaling network may provide an attractive target
for therapeutic intervention [9]. However, little is known about
how the small molecule inhibitors of TGF-b receptor kinase
activity might regulate the tumor-suppressive or tumor-
promoting effects of TGF-b, and when these inhibitors will
be useful for treatment during cancer progression. In the
Figure 6. SB-431542 abrogates TGF- – induced migration, invasion, wound healing, and COX-2 expression. (A) Migration assay. A549 cells were treated with
TGF-, and SB-431542 cells were allowed to migrate through a 8-M pore in transwells. Cells that migrated through the pores were stained and counted. The data
were represented as the mean ± SD of three independent wells. (B and C) Invasion assays. A549 cells were treated as above and allowed to pass through
collagen-coated (B) and Matrigel-coated (C) membrane in transwells. Cells that invaded through the filter were stained and counted. Individual data point is
represented as the mean ± SD of three independent wells. (D) Wound healing. Wounded MDA-MB-231 cells were treated with 3 ng/ml TGF-1 for 30 hours in the
presence of SB-431542. Phase contrast images were shown. All of these experiments were repeated four times. (E) Growth inhibition of MDA-MB-231 cells by
TGF- was determined by cell counting (left) and thymidine incorporation (right) assays as described before. (F) Effect of SB-431542 on TGF- – induced COX-2
expression. Oncogenic Ras-inducible rat intestinal epithelial (RIE-iRas) cells were treated with 5 mM IPTG and/or 5 ng/ml TGF-1 in the presence of SB-431542
(10 M) for 24 hours. Cell lysates were analyzed by Western blot analysis with anti –COX-2 (Santa Cruz Biotechnology) and anti –Pan-Ras (Oncogene Research
Products) antibodies. An equal amount of protein loading was verified by Western blot analysis with anti –-actin antibody. This experiment was repeated three
times with similar results.
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present study, we have demonstrated that SB-431542, a
novel ALK5 kinase inhibitor, inhibits the tumor-suppressive
function of TGF-b including growth inhibition and apoptosis in
several cell types. In contrast, SB-431542 abrogates the pro-
oncogenic functions of TGF-b including cell migration, inva-
sion, VEGF secretion, and EMT. We also demonstrate that
SB-431542 induces anchorage-independent growth of A549
cells that are growth-inhibited by TGF-b. Interestingly, this
inhibitor decreases the tumorigenicity of highly aggressive
HT29 cells that are growth-stimulated by TGF-b. However,
SB-431542 has no effect on colony formation by VMRC-LCD
cells that are not responsive to TGF-b. These studies sug-
gest that small molecule inhibitors of TGF-b receptor kinase
activity may be useful in developing a new therapeutic
strategy for the treatment of cancers that are resistant to
TGF-b–mediated tumor-suppressor function.
A previous study demonstrated that SB-431542 inhibits
the activity of ALK5, ALK4, and ALK7, but it has no effect on
BMP signaling. However, SB-431542 has no direct effect on
ERK, JNK, or p38 MAP kinase pathways [15,16]. Our study
with SB-431542 is significant in several ways. We show
that this small molecule inhibitor of TGF-b receptor kinase
activity blocks both tumor-suppressing function and tumor-
promoting activity of TGF-b. Previous studies with soluble
Fc:TbRII, used either as an injectable drug [13] or when
stably expressed as a transgene [12], antagonize TGF-b sig-
naling and reduce mammary tumor metastasis to the lung.
The most encouraging observation in these studies is that
soluble Fc:TbRII did not induce tumor-promoting effects by
blocking TGF-b–mediated antitumor effects. Consistent
with these data, our study indicates that SB-431542 does
not completely block the growth-inhibitory effect of TGF-b in
normal epithelial cells. We observed that the growth of HT29
cells is stimulated by TGF-b. Interestingly, the growth of
HT29 cells induced by both endogenous and exogenous
TGF-b was efficiently blocked by SB-431542. This is consis-
tent with previous reports suggesting that SB-421542 inhibits
TGF-b–induced proliferation of human glioma cells [26] and
human osteosarcoma cells [27]. The expression of TGF-b,
particularly TGF-b1, is increased in various tumor types that
correlate with the poor patient prognosis [25]. Oft et al. [28]
reported that autocrine TGF-b signaling is required for the
induction of EMT, invasiveness, and metastasis. We found
that TGF-b–induced EMT was blocked by SB-431542 in
NMuMG mouse mammary epithelial cells (Figure 5A) and in
PANC-1 human pancreatic cancer cell line (Figure 5C) by
reversing delocalization and/or downregulation of junctional
proteins. TGF-b downregulates ZO1 in NMuMG cells and
E-cadherin in PANC-1 cells as shown in Figure 5, B and D.
As EMT is a frequent event in the late stage of human
carcinoma and TGF-b signaling is involved in EMT main-
tenance, blockade of EMT by the inhibitor increases its
effectiveness as anticancer drug. We have shown that SB-
431542 blocks the migration and invasion of tumor cells
mediated by both endogenous and exogenous TGF-b, sug-
gesting a potential role of the inhibitor in blocking metastasis.
Induction in COX-2 expression in human cancers is
known to promote tumor growth, increase tumor cell inva-
sion, and enhance tumor angiogenesis. Increased level of
TGF-b in tumors may contribute to upregulation of COX-2
activity. Our study shows that SB-431542 can inhibit TGF-b–
induced COX-2 expression, suggesting an effect of the
inhibitor in blocking oncogenic functions of COX-2. Tumor
angiogenesis is critical for the progressive growth and me-
tastasis of a neoplasm. Increased TGF-b production in the
tumor can induce the angiogenic factor, VEGF. Interestingly,
the VEGF production in both A549 and HT29 cells is inhibited
by SB-431542. These cells express a significant amount of
TGF-b; however, this expression is not affected by the
inhibitor. Although VMRC-LCD cells produce a similar
amount of TGF-b, we did not see any change in the level
of VEGF by TGF-b or SB-431542. This is because these
cells are not responsive to TGF-b due to the lack of TbRII.
These results suggest that the attenuated secretion of VEGF
in cancer cell lines is through the blockade of TGF-b signal
transduction pathway and not by blocking TGF-b secretion.
In this study, we also provide evidence regarding when
these small molecule inhibitors will be useful as thera-
peutic agents during cancer progression. We have observed
Figure 7. SB-431542 blocks TGF- – induced VEGF secretion. A549 (A) and
HT29 (B) cells were treated with 5 ng/ml TGF-1 in the presence of SB-
431542 (10 M) for 24 hours. Supernatant media were analyzed for VEGF
secretion by ELISA. (C) ELISA for TGF-1. A549, VMRC-LCD, and HT29
cells express similar amounts of TGF-1. Cells were treated with SB-431542
for 24 hours. Supernatant media were activated and used for TGF-1 assay.
Individual data point in either VEGF or TGF- assay is a representative of the
mean ± SD of three individual measurements. Each experiment is repeated
at least three times.
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differential effects of SB-431542 on the tumorigenic po-
tential of different cancer cell lines. SB-431542 induces
anchorage-independent growth of A549 cells as evident from
both colony number and size in the soft agar assay. In
contrast, SB-431542 dramatically suppressed the colony
growth of HT29 cells. However, SB-431542 has no effect
on colony formation in the case of VMRC-LCD cells that are
not responsive to TGF-b due to lack of TbRII expression
(Ref. [29] and unpublished data). HT29 cells have functional
receptor complex, but lack Smad4. Therefore, these cells do
not have a functional Smad pathway that is thought to be
important for TGF-b–induced growth inhibition. However,
TGF-b still can send signals in these cells through non-Smad
pathways including ERK, p38 MAPK, JNK, PI3K, etc., which
are supposed to be involved in pro-oncognic functions of
TGF-b. In the HT29 cell line SB-431542 can block TGF-b
signaling through these non-Smad pathways. In this cell line,
SB-431542 inhibits the growth-stimulatory effects of en-
dogenous TGF-b (Figure 8F ). In contrast, A549 cells have
an intact classic TGF-b–mediated growth-inhibitory Smad
signaling (Figure 1A), which is inhibited by SB-431542.
Interestingly, the endogenous TGF-b secreted by A549
cells inhibits growth and SB-431542 increases tumorige-
nicity by attenuating the growth-inhibitory effects of TGF-b
(Figure 8B). SB-431542 has been shown to reduce TGF-b–
induced inhibition of proliferation of embryonic stem cell–
derived endothelial cells [30]. In VMRC-LCD cells, Smad and
non-Smad pathways are not activated by TGF-b due to the
absence of TbRII.
In conclusion, SB-431542 cannot block the tumorigenic
growth of cancer cell lines that are either unresponsive to
TGF-b, or are growth-inhibited by TGF-b. Abrogation of
TGF-b–induced pro-oncogenic effects by SB-431542 de-
creases the tumorigenic potential of cancer cells. These
inhibitors may also block paracrine pro-oncogenic effects
of TGF-b produced by tumors that lack functional TGF-b
receptors. Although the loss of TGF-b receptors in solid
tumors is a rare event outside the GI tract, TbRII levels are
reduced in many advanced human tumors through epige-
netic mechanisms [10]. This low level of TbRII activation may
facilitate pro-oncogenic effects in the advanced stage of
human cancers (Figure 9). Our results from this preclinical
Figure 8. Differential effects of SB-431542 on anchorage-independent growth of different cell lines. (A, C, and E) Soft agarose assay. A549, VMRC-LCD, and
HT29 cells were plated and treated with SB-431542 (10 M) for 2 weeks. Pictures of colonies grown on soft agarose were shown. (G) Colonies were counted by
automated colony counter and the data are represented as the mean ± SD of three individual plates. (B, D, and F) Cell counting assay. A549 (B), VMRC-LCD (D),
and HT29 (F) cells were treated with 7 ng/ml TGF-1 in the presence of SB-431542 (10 M) for a total of 6 days. Cells were counted and the results are plotted.
Individual data points are the mean ± SD of triplicate determinations. Each experiment was repeated three times.
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study suggest that SB-431542 could be a potential thera-
peutic agent when tumors are resistant to TGF-b–induced
growth suppression and apoptosis, and when tumor-promoting
effects of TGF-b predominate during cancer progression
(taking colorectal cancer as an example; Figure 9). Because
an elevated level of TGF-b has been known to be associated
with poor prognosis in a wide variety of human tumors, small
molecule inhibitors of TGF-b activity could be useful for a
developing therapeutic strategy for treating cancers refrac-
tory to classic antitumor agents. This study also suggests
that identification of the mechanism underlying divergent
responses (pro- and anti-oncogenic) may yield more specific
therapeutic targets for novel small molecule inhibitors that
would, ideally, preserve tumor-suppressive effects while
abrogating the tumor-promoting effects of TGF-b.
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